Campbell & CO Investment Adviser LLC Makes New $390,000 Investment in GlaxoSmithKline plc (NYSE:GSK)

Campbell & CO Investment Adviser LLC bought a new position in GlaxoSmithKline plc (NYSE:GSK) during the third quarter, Holdings Channel.com reports. The fund bought 10,352 shares of the pharmaceutical company’s stock, valued at approximately $390,000.

A number of other hedge funds also recently modified their holdings of the business. TRUE Private Wealth Advisors grew its stake in GlaxoSmithKline by 17.8% in the 2nd quarter. TRUE Private Wealth Advisors now owns 1,656 shares of the pharmaceutical company’s stock worth $68,000 after acquiring an additional 250 shares in the last quarter. Capital Investment Advisors LLC grew its stake in GlaxoSmithKline by 4.5% in the 2nd quarter. Capital Investment Advisors LLC now owns 5,985 shares of the pharmaceutical company’s stock worth $244,000 after acquiring an additional 259 shares in the last quarter. First Command Bank grew its stake in GlaxoSmithKline by 38.1% in the 2nd quarter. First Command Bank now owns 975 shares of the pharmaceutical company’s stock worth $39,000 after acquiring an additional 269 shares in the last quarter. Keeler Thomas Management LLC boosted its stake in shares of GlaxoSmithKline by 2.0% during the second quarter. Keeler Thomas Management LLC now owns 13,846 shares of the pharmaceutical company’s stock valued at $564,000 after purchasing an additional 271 shares in the last quarter. Finally, Bessemer Group Inc. boosted its stake in shares of GlaxoSmithKline by 2.1% during the second quarter. Bessemer Group Inc. now owns 13,344 shares of the pharmaceutical company’s stock valued at $545,000 after purchasing an additional 271 shares in the last quarter. Institutional investors and hedge funds own 12.12% of the company’s stock.

GSK has been the topic of a number of recent research reports. UBS Group reiterated a “buy” rating on shares of GlaxoSmithKline in a research note on Monday, October 12th. AlphaValue upgraded shares of GlaxoSmithKline to a “buy” rating in a research note on Tuesday, September 1st. Oddo Bhf upgraded shares of GlaxoSmithKline from a “neutral” rating to a “buy” rating in a research note on Wednesday, September 23rd. Credit Suisse Group reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Monday, October 5th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Tuesday, September 8th. Four research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $41.00.

In related news, Director Plc Glaxosmithkline purchased 361,111 shares of the firm’s stock in a transaction on Tuesday, July 21st. The stock was acquired at an average price of $18.00 per share, with a total value of $6,499,998.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 10.00% of the company’s stock.

NYSE:GSK opened at $36.57 on Friday. GlaxoSmithKline plc has a 52 week low of $31.43 and a 52 week high of $48.25. The firm has a 50 day moving average of $38.30 and a 200 day moving average of $40.21. The company has a quick ratio of 0.69, a current ratio of 0.96 and a debt-to-equity ratio of 1.28. The stock has a market capitalization of $91.74 billion, a price-to-earnings ratio of 10.85, a PEG ratio of 2.76 and a beta of 0.65.

GlaxoSmithKline (NYSE:GSK) last posted its earnings results on Wednesday, July 29th. The pharmaceutical company reported $0.48 EPS for the quarter, missing the Zacks’ consensus estimate of $0.49 by ($0.01). GlaxoSmithKline had a net margin of 19.03% and a return on equity of 31.21%. The firm had revenue of $9.46 billion for the quarter, compared to analysts’ expectations of $9.60 billion. As a group, analysts expect that GlaxoSmithKline plc will post 3.01 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Thursday, October 8th. Shareholders of record on Friday, August 14th were issued a $0.4914 dividend. The ex-dividend date of this dividend was Thursday, August 13th. This represents a $1.97 dividend on an annualized basis and a dividend yield of 5.38%. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.47. GlaxoSmithKline’s dividend payout ratio (DPR) is currently 61.20%.

GlaxoSmithKline Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Further Reading: How accurate is the Rule of 72?

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.